CA
NZ
UK
AU
IND
US
…
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
| Income before tax | -187.00M | -203.00M | -70.00M | -76.00M |
| Minority interest | -16.00M | -15.00M | -5.00M | -5.00M |
| Net income | -331.00M | -250.00M | -112.00M | -96.00M |
| Selling general administrative | 1183.00M | 1131.00M | 1057.00M | 960.00M |
| Selling and marketing expenses | - | 1131.00M | 1057.00M | 960.00M |
| Gross profit | 1680.00M | 1525.00M | 1436.00M | 1308.00M |
| Reconciled depreciation | 156.00M | 143.00M | 129.00M | 115.00M |
| Ebit | - | -36.00M | -70.00M | -76.00M |
| Ebitda | 49.00M | 107.00M | 59.00M | 39.00M |
| Depreciation and amortization | - | 143.00M | 129.00M | 115.00M |
| Operating income | 49.00M | -202.00M | -69.00M | -69.00M |
| Other operating expenses | 3053.00M | 2917.00M | 2538.00M | 2314.00M |
| Tax provision | 128.00M | 48.00M | 38.00M | 16.00M |
| Income tax expense | 128.00M | 48.00M | 38.00M | 16.00M |
| Total revenue | 3102.00M | 2715.00M | 2469.00M | 2245.00M |
| Total operating expenses | 1631.00M | 1727.00M | 1506.00M | 1377.00M |
| Cost of revenue | 1422.00M | 1190.00M | 1032.00M | 937.00M |
| Total other income expense net | -236.00M | -1.00M | -1.00M | -7.00M |
| Net income from continuing ops | -317.00M | -251.00M | -108.00M | -92.00M |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
| Total assets | 4630.00M | 4201.00M | 4094.00M | - |
| Intangible assets | 106.00M | 131.00M | 160.00M | - |
| Other current assets | 54.00M | 48.00M | 42.00M | - |
| Total liab | 1019.00M | 870.00M | 646.00M | - |
| Total stockholder equity | 3611.00M | 3331.00M | 3448.00M | - |
| Other current liab | 341.00M | 483.00M | 309.00M | - |
| Common stock | 3.00M | - | - | - |
| Capital stock | 3.00M | 0.00M | - | - |
| Retained earnings | -116.00M | 0.00M | - | - |
| Good will | 2256.00M | 2255.00M | 2255.00M | - |
| Other assets | 1.00M | 1.00M | 1.00M | - |
| Cash | 298.00M | 11.00M | 54.00M | - |
| Total current liabilities | 702.00M | 710.00M | 518.00M | - |
| Current deferred revenue | 15.00M | 11.00M | 11.00M | - |
| Net debt | -153.00M | - | -46.00M | - |
| Short term debt | 145.00M | 11.00M | 8.00M | - |
| Short long term debt | 137.00M | - | - | - |
| Short long term debt total | 145.00M | 11.00M | 8.00M | - |
| Other stockholder equity | 3736.00M | 3328.00M | 3464.00M | - |
| Total current assets | 1348.00M | 939.00M | 895.00M | - |
| Net receivables | 655.00M | 570.00M | 507.00M | - |
| Inventory | 341.00M | 310.00M | 292.00M | - |
| Accounts payable | 163.00M | 205.00M | 190.00M | - |
| Accumulated other comprehensive income | -12.00M | 3.00M | -16.00M | - |
| Non currrent assets other | 208.00M | 169.00M | 147.00M | - |
| Non current assets total | 3281.00M | 3261.00M | 3198.00M | - |
| Capital lease obligations | 8.00M | 11.00M | 8.00M | - |
| Breakdown | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2026-04-30 | 2025-04-30 | 2024-04-30 | 2023-04-30 |
| Investments | 0.00M | 0.00M | 6.00M | -13.00M |
| Total cashflows from investing activities | -233.00M | -193.00M | -157.00M | -180.00M |
| Total cash from financing activities | 716.00M | 10.00M | 112.00M | 185.00M |
| Net income | -317.00M | -198.00M | -107.00M | -92.00M |
| Change in cash | 287.00M | -43.00M | -4.00M | -2.00M |
| Begin period cash flow | 11.00M | 54.00M | 58.00M | 60.00M |
| End period cash flow | 298.00M | 11.00M | 54.00M | 58.00M |
| Total cash from operating activities | -197.00M | 140.00M | 41.00M | -6.00M |
| Issuance of capital stock | 538.00M | 0.00M | 0.00M | - |
| Depreciation | 156.00M | 143.00M | 129.00M | 115.00M |
| Other cashflows from investing activities | -10.00M | - | -15.00M | - |
| Change to inventory | -29.00M | -19.00M | 5.00M | -28.00M |
| Change to account receivables | -538.00M | -66.00M | -105.00M | -70.00M |
| Other cashflows from financing activities | 178.00M | 10.00M | 112.00M | 185.00M |
| Capital expenditures | 223.00M | 193.00M | 148.00M | 167.00M |
| Change in working capital | -166.00M | 122.00M | -74.00M | -90.00M |
| Stock based compensation | 46.00M | 41.00M | 38.00M | 35.00M |
| Other non cash items | 138.00M | 34.00M | 52.00M | 37.00M |
| Free cash flow | -420.00M | -53.00M | -107.00M | -173.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MMED MiniMed Group, Inc. Common Stock |
-1.45 7.96% |
16.71 | - | - | 1.92 | 1.71 | 1.86 | 92.94 |
| ISRG Intuitive Surgical Inc |
-15.72 3.36% |
452.80 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
2.75 1.29% |
215.85 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
0.92 0.86% |
107.77 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
-1.69 0.79% |
211.86 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
18000 Devonshire Street, Northridge, CA, United States, 91325
763 514 4000
8000
| Name | Title | Year Born |
|---|---|---|
| Ms. Que Thanh Dallara | CEO & Director | 1974 |
| Mr. Chad J. Spooner | Executive VP & CFO | 1972 |
| Mr. Ali Dianaty | Executive VP and Chief Product & Technology Officer | 1975 |
| Ms. Courtney Nelson Wills | SVP, General Counsel & Corporate Secretary | 1976 |
| Ms. Gillian Chandrasena | Senior VP & Chief Human Resources Officer | 1974 |
| Mr. Christopher E. Eso | President | NA |
| Mr. John Gyurci | VP, Chief Accounting Officer & Controller | 1971 |
| Mr. Mike Bruggeman | SVP & Chief Information Officer | NA |
| Mr. Ryan Weispfenning | Head of Investor Relations | NA |
| Ms. Kate Cronin MSN RN | SVP & Chief Marketing Officer | 1966 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...